Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)

Randomized, Double-blind, Parallel-group, Phase 3 Study

This is the trial to see how our product is similar to remicade by comparing the results of blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose and folic acid in rheumatoid arthritis patients who are not receiving adequate response to methotrexate alone up to week 30.

Inclusion Criteria:

• diagnosed with active rheumatoid arthritis
• at least 3 months of treatment with methotrexate

Exclusion Criteria:

• have allergies to infliximab
• serious infection